Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally ...

However, the stock took a hit after Eli Lilly lowered its full-year earnings outlook, attributing this to a $1.57 billion charge from acquiring an oral cancer drug from Scorpion Therapeutics.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

The company also raised its full-year outlook, and the stock rallied over 15% since it reported the Q2 numbers. In this note, we discuss Eli Lilly’s stock performance, key takeaways from its ...

Revenue Outlook ... momentum." Eli Lilly. "Estimated First Quarter 2025 Acquired In-Process Research and Development (“IPR&D”) Charges." What Analysts Think of Broadcom Stock Ahead of Earnings ...

Eli Lilly (NYSE: LLY) stock has been a winner for investors of ... Eli Lilly increased its 2024 total revenue outlook by $2 billion to a range of $42.4 billion-$43.6 billion, owing to strong ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential ... so on that basis, the stock is very inexpensive. The GLP-1 market continues ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...